Supernus Pharmaceuticals Q3 revenue rises 18% on CNS growth

Overview

• U.S. CNS drugmaker's Q3 total revenue rose 18% yr/yr on strong growth products

• Adjusted operating earnings for Q3 increased from prior year, driven by higher revenue

• Company expects Indivior merger to close Nov. 2, creating larger CNS biopharma

Outlook

• Company raises 2026 full-year revenue guidance to $875 mln-$900 mln

• Supernus expects 2026 adjusted operating earnings of $160 mln-$180 mln

• Company says 2026 guidance will no longer apply after Indivior merger closes Nov. 2, 2026

Result Drivers

• GROWTH PRODUCTS - Co said revenue growth was driven by higher net sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO

• ZURZUVAE COLLABORATION - Collaboration revenue from ZURZUVAE more than doubled, with U.S. sales reported by Biogen up 53% yr/yr

• ONAPGO DEMAND - ONAPGO net sales more than doubled, supported by prescription growth and orphan-drug approval

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Supernus Pharmaceuticals, Inc. is $65.00, about 58.2% above its October 28 closing price of $41.08

• The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads

• Oct 29 - Indivior Pharmaceuticals tops Q3 revenue estimates, net income hits record

• Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

• Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)